HomeAbout

TL;DR CNBC


Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial - TL;DR CNBC

Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial

Publishing timestamp: 2024-04-04 13:09:08


Summary

A diabetes drug called lixisenatide, made by Sanofi, showed potential to help patients with Parkinson's disease by slowing the progression of motor disability in a small mid-stage trial. Larger studies are needed to fully determine efficacy and safety, but the results are seen as an encouraging step forward in the effort to tackle Parkinson's disease.


Sentiment: MIXED

Tickers: NOVO.B-DKLLYSNYSAN-FRNVO

Keywords: novo nordisk a/ssanofi sahealth care industrypharmaceuticalssciencebiotech and pharmaceuticalseli lilly and cobusinessbusiness newsbiotechnology

Source: https://www.cnbc.com/2024/04/04/drug-similar-to-ozempic-slowed-parkinsons-disease-in-small-trial.html


Developed by Leo Phan